National

After Serum Institute's Covishield, expert panel approves Bharat Biotech's Covaxin

An expert panel of India's central drug authority on Saturday recommended granting permission for restricted emergency use of the indigenously developed COVID-19 vaccine Covaxin with certain conditions, a day after giving similar direction for the Oxford COVID-19 vaccine, sources said.

migrator

Updated:2nd Jan, 2021 at 7:20 PM

New Delhi

Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Saturday again deliberated on the emergency use authorisation (EUA) application of the Hyderabad-based pharmaceutical firm after it submitted additional data, facts and analysis subsequent to Friday's review meeting, a source said.

Bharat Biotech had applied to the Drugs Controller General Of India (DCGI) seeking emergency use authorisation for its Covaxin on December 7.

On Friday, the SEC had recommended granting permission for restricted emergency use of Oxford-AstraZeneca vaccine Covishield, being manufactured by the Serum Institute of India.

After Serum Institute's Covishield, expert panel approves Bharat Biotech's Covaxin

An expert panel of India's central drug authority on Saturday recommended granting permission for restricted emergency use of the indigenously developed COVID-19 vaccine Covaxin with certain conditions, a day after giving similar direction for the Oxford COVID-19 vaccine, sources said.

Also Read

Veeramani case under CM Vijay’s direct supervision, says Minister Rajmohan

'One-man autocracy' under CEC, Gyanesh Kumar must be removed: Oppn after report on differences in poll panel

Submerged Chola port city yields fresh secrets, throws up torpedo jar during exploration

TN nurses body announces agitation over contractual appointments

CM Vijay reviews power supply amid complaints of frequent outages